251 related articles for article (PubMed ID: 27513584)
21. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.
Williams MT; Farris SG; Turkheimer EN; Franklin ME; Simpson HB; Liebowitz M; Foa EB
J Anxiety Disord; 2014 Aug; 28(6):553-8. PubMed ID: 24983796
[TBL] [Abstract][Full Text] [Related]
22. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
23. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
[TBL] [Abstract][Full Text] [Related]
24. The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis.
Ivarsson T; Skarphedinsson G; Kornør H; Axelsdottir B; Biedilæ S; Heyman I; Asbahr F; Thomsen PH; Fineberg N; March J;
Psychiatry Res; 2015 May; 227(1):93-103. PubMed ID: 25769521
[TBL] [Abstract][Full Text] [Related]
25. Combination of CBT with fluoxetine works better for obsessive-compulsive disorder.
Giasuddin NA; Nahar JS; Morshed NM; Balhara YP
Asian J Psychiatr; 2012 Mar; 5(1):113. PubMed ID: 26878959
[No Abstract] [Full Text] [Related]
26. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
Yoshimura R; Kaneko S; Shinkai K; Nakamura J
Psychiatry Clin Neurosci; 2006 Jun; 60(3):389-93. PubMed ID: 16732759
[TBL] [Abstract][Full Text] [Related]
27. [To identify and treat obsessive-compulsive disorders: an overview].
Voderholzer U; Hauer M; Stattrop U
MMW Fortschr Med; 2013 Sep; 155(15):37-9. PubMed ID: 24224373
[No Abstract] [Full Text] [Related]
28. Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.
Simpson HB; Foa EB; Wheaton MG; Gallagher T; Gershkovich M; Schmidt AB; Huppert JD; Campeas RB; Imms PA; Cahill SP; DiChiara C; Tsao SD; Puliafico AC; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanchez-LaCay A; Capaldi S; Snorrason I; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hahn CG; Xu B; Van Meter PE; Katechis M; Scodes J; Wang Y
Behav Res Ther; 2021 Aug; 143():103890. PubMed ID: 34089924
[TBL] [Abstract][Full Text] [Related]
29. Obsessive compulsive disorder.
Soomro GM
Clin Evid; 2003 Dec; (10):1172-87. PubMed ID: 15555141
[No Abstract] [Full Text] [Related]
30. Special issue: Update on the nature and treatment of obsessive-compulsive-related disorders.
Stanley M; Björgvinsson T; Frueh BC
Bull Menninger Clin; 2010; 74(2):iii-vi. PubMed ID: 20545490
[No Abstract] [Full Text] [Related]
31. Augmenting treatment of obsessive-compulsive disorder with Antonovsky's sense of coherence theory.
Joachim B; Lyon DD; Farrell SP
Perspect Psychiatr Care; 2003; 39(4):163-8. PubMed ID: 14737822
[TBL] [Abstract][Full Text] [Related]
32. Obsessive compulsive disorder.
Soomro GM
Clin Evid; 2004 Jun; (11):1319-34. PubMed ID: 15652061
[No Abstract] [Full Text] [Related]
33. Obsessive-compulsive disorder in Tourette syndrome.
Goodman WK; Storch EA; Geffken GR; Murphy TK
J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
[TBL] [Abstract][Full Text] [Related]
34. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
Ramasubbu R
Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
[No Abstract] [Full Text] [Related]
35. [Cognitive-behavior therapy for obsessive-compulsive disorder: a systematic review of the last decade].
Prazeres AM; Souza WF; Fontenelle LF
Braz J Psychiatry; 2007 Sep; 29(3):262-70. PubMed ID: 17713699
[TBL] [Abstract][Full Text] [Related]
36. Obsessive compulsive disorder.
Soomro GM
Clin Evid; 2005 Dec; (14):1270-83. PubMed ID: 16620454
[No Abstract] [Full Text] [Related]
37. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
38. Possible dose-response relationship for risperidone in obsessive-compulsive disorder.
Baker RW
J Clin Psychiatry; 1998 Mar; 59(3):134. PubMed ID: 9541161
[No Abstract] [Full Text] [Related]
39. Cognitive-behavioral group therapy versus sertraline for obsessive-compulsive disorder: five-year follow-up.
Borges CP; Meyer E; Ferrão YA; Souza FP; Sousa MB; Cordioli AV
Psychother Psychosom; 2011; 80(4):249-50. PubMed ID: 21540627
[No Abstract] [Full Text] [Related]
40. Commonly asked questions in the treatment of obsessive-compulsive disorder.
Arumugham SS; Reddy YC
Expert Rev Neurother; 2014 Feb; 14(2):151-63. PubMed ID: 24372473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
